GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » E10

EyePoint Pharmaceuticals (STU:PV3B) E10 : €-5.86 (As of Mar. 2025)


View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

EyePoint Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was €-0.601. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-5.86 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average E10 Growth Rate was -2.70% per year. During the past 5 years, the average E10 Growth Rate was 0.30% per year. During the past 10 years, the average E10 Growth Rate was 19.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of EyePoint Pharmaceuticals was 56.90% per year. The lowest was -5.30% per year. And the median was 7.20% per year.

As of today (2025-07-25), EyePoint Pharmaceuticals's current stock price is €9.00. EyePoint Pharmaceuticals's E10 for the quarter that ended in Mar. 2025 was €-5.86. EyePoint Pharmaceuticals's Shiller PE Ratio of today is .


EyePoint Pharmaceuticals E10 Historical Data

The historical data trend for EyePoint Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals E10 Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.14 -5.11 -5.25 -4.69 -5.54

EyePoint Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.89 -4.90 -5.46 -5.54 -5.86

Competitive Comparison of EyePoint Pharmaceuticals's E10

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Shiller PE Ratio falls into.


;
;

EyePoint Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EyePoint Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.601/134.9266*134.9266
=-0.601

Current CPI (Mar. 2025) = 134.9266.

EyePoint Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201506 -1.515 100.684 -2.030
201509 -1.515 100.392 -2.036
201512 -1.652 99.792 -2.234
201603 -1.347 100.470 -1.809
201606 -1.691 101.688 -2.244
201609 -1.871 101.861 -2.478
201612 -0.019 101.863 -0.025
201703 -1.402 102.862 -1.839
201706 -1.424 103.349 -1.859
201709 -1.259 104.136 -1.631
201712 -1.098 104.011 -1.424
201803 -1.216 105.290 -1.558
201806 -5.307 106.317 -6.735
201809 -3.771 106.507 -4.777
201812 -0.791 105.998 -1.007
201903 -1.770 107.251 -2.227
201906 -0.974 108.070 -1.216
201909 -1.362 108.329 -1.696
201912 -0.900 108.420 -1.120
202003 -1.032 108.902 -1.279
202006 -0.924 108.767 -1.146
202009 -0.255 109.815 -0.313
202012 -0.880 109.897 -1.080
202103 -0.420 111.754 -0.507
202106 -0.291 114.631 -0.343
202109 -0.493 115.734 -0.575
202112 -0.522 117.630 -0.599
202203 -0.508 121.301 -0.565
202206 -0.492 125.017 -0.531
202209 -0.495 125.227 -0.533
202212 -1.095 125.222 -1.180
202303 -0.523 127.348 -0.554
202306 -0.563 128.729 -0.590
202309 -0.309 129.860 -0.321
202312 -0.293 129.419 -0.305
202403 -0.506 131.776 -0.518
202406 -0.539 132.554 -0.549
202409 -0.487 133.029 -0.494
202412 -0.611 133.157 -0.619
202503 -0.601 134.927 -0.601

Add all the adjusted EPS together and divide 10 will get our e10.


EyePoint Pharmaceuticals  (STU:PV3B) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


EyePoint Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals Headlines

No Headlines